Irinotecan Kabi (Irinotecan Hydrochloride Trihydrate)

• Irinotecan Kabi is a topoisomerase I inhibitor used in colorectal cancer treatment pathways.
• Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based regimens.
• Adjuvant therapy for colon cancer: reduces risk of disease recurrence after curative surgery.
• Colorectal cancer (in combination therapy): enhances tumor response when used with other cytotoxic agents.

• After intravenous administration, Irinotecan is converted by hepatic carboxylesterases to the active metabolite SN‑38. SN‑38 binds to the DNA‑topoisomerase I complex, stabilizing it and preventing relegation of single‑strand DNA breaks. This inhibition blocks DNA replication and transcription, leading to apoptosis of rapidly dividing cancer cells.

Irinotecan Kabi may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Diarrhea: often severe and may require antidiarrheal therapy.
• Neutropenia: reduced white blood cell count increasing infection risk.
• Nausea and vomiting: may be managed with antiemetics.
• Alopecia: temporary hair loss.
• Fatigue: generalized tiredness.
• Abdominal cramping: discomfort in the stomach area.

Serious or Rare Side Effects

• Severe neutropenic infection: febrile neutropenia requiring hospitalization.
• Life‑threatening diarrhea: may lead to dehydration and electrolyte imbalance.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.
• Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis.
• Cardiac toxicity: rare arrhythmias or ischemic events.
• Secondary malignancies: potential long‑term risk of new cancers.

• Before initiating Irinotecan Kabi, clinicians should assess patient-specific risk factors and monitor laboratory parameters.
• Baseline blood counts: verify adequate neutrophil and platelet levels.
• Liver function: evaluate hepatic enzymes due to metabolism dependence.
• Renal function: adjust monitoring if creatinine clearance is impaired.
• Pregnancy: avoid use; drug is classified Category D and may cause fetal harm.
• Concomitant medications: review for agents that may exacerbate neutropenia or diarrhea.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake the solution.

Irinotecan Kabi can interact with several drugs that affect its metabolism or toxicity profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase SN‑38 exposure.
• UGT1A1 inhibitors (e.g., atazanavir): raise risk of severe neutropenia.
• High‑dose irinotecan with other myelosuppressive agents: may cause life‑threatening bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

• Anticholinergic agents: may worsen constipation and abdominal cramping.
• Anticoagulants (e.g., warfarin): monitor INR for bleeding risk.
• Proton pump inhibitors: potential alteration of gastrointestinal absorption.
• Diuretics: monitor electrolytes during severe diarrhea.
• Herbal supplements affecting liver enzymes: assess for possible interaction.